scholarly journals Determination of clinical state of hepatitis B virus infection of patients in Basra governorate

2012 ◽  
Vol 36 (0E) ◽  
pp. 72-75
Author(s):  
Saad S. Hamadi

Hepatitis B virus is a hepatotropic virus that causes acute and chronic hepatitis, livercirrhosis and hepatocellular carcinoma; it is responsible for more than one million deathsannually worldwide despite hepatitis B vaccination. So, the aim of the present study was todetect the total markers of HBV (HBsAg, HBsAb, HBeAg, HBeAb, Total anti-HBc and IgManti-HBc) .A total of 126 cases with hepatitis B were recruited from different medical centersin Basra. Serological tests were preformed for all cases using ELISA tests. 126 patients weredivided into 8 studied groups including: Incubation, Active acute, Acute, Active chronic,chronic, Inactive HBsAg Carrier, HBsAg-negative patients and liver cancer. We conclude thatthe vast majority of patients were Inactive HBsAg Carrier (54.76 %) fallowed by acutehepatitis (16.67 %) and HBsAg-negative patients (7.14 %).

Vaccines ◽  
2021 ◽  
Vol 9 (2) ◽  
pp. 82
Author(s):  
Karen K. Kyuregyan ◽  
Vera S. Kichatova ◽  
Olga V. Isaeva ◽  
Ilya A. Potemkin ◽  
Elena Yu. Malinnikova ◽  
...  

Universal hepatitis B vaccination of newborns was implemented in Russia starting from 1998. From 1998 to 2019, the incidence of acute hepatitis B reduced from 43.8 to 0.57 cases per 100,000 population. Here, we assessed the timely coverage of newborns with the birth dose (HepB-BD), second dose (HepB-2nd), and three vaccine doses (HepB3) in two remote regions of Russia with low (Belgorod Oblast) and high (Yakutia) levels of hepatitis B virus (HBV) endemicity. Vaccination data were obtained from the medical records of 1000 children in Yakutia and 2182 children in Belgorod Oblast. Sera of healthy volunteers from Belgorod Oblast (n = 1754) and Yakutia (n = 1072) across all age groups were tested for serological markers of HBV to assess the infection prevalence and herd immunity. Average HepB-BD coverage was 99.2% in Yakutia and 89.4% in Belgorod Oblast (p < 0.0001) and in both regions varied significantly, from 66% to 100%, between medical centers. The principal reason for the absence of HepB-BD was parent refusal, which accounted for 63.5% of cases of non-vaccination (83/123). While timely HepB-2nd coverage was only 55.4%–64.7%: HepB3 coverage by the age of one year exceeded 90% in both study regions. HBV surface antigen (HBsAg) prevalence in the 1998–2019 birth cohort was 0.2% (95% CI: 0.01–1.3%) in Belgorod Oblast and 3.2% (95% CI: 1.9–5.2%) in Yakutia. The proportion of persons testing negative for both antibodies to HBsAg (anti-HBs) and antibodies to HBV core antigen (anti-HBc) in the 1998–2019 birth cohort was 26.2% (125/481) in Belgorod Oblast and 32.3% (162/501) in Yakutia. We also assessed the knowledge of and attitude towards vaccination among 782 students and teachers of both medical and non-medical specialties from Belgorod State University. Only 60% of medical students knew that hepatitis B is a vaccine-preventable disease. Both medical and nonmedical students, 37.8% and 31.3%, respectively, expressed concerns about safety and actual necessity of vaccination. These data indicate the need to introduce a vaccine delivery audit system, improve medical education with respect to vaccination strategies and policies, and reinforce public knowledge on the benefits of vaccination.


1992 ◽  
Vol 73 (11) ◽  
pp. 3005-3009 ◽  
Author(s):  
A. Uy ◽  
G. Wunderlich ◽  
D. B. Olsen ◽  
K.-H. Heermann ◽  
W. H. Gerlich ◽  
...  

2018 ◽  
Vol 41 (4) ◽  
pp. 765-771 ◽  
Author(s):  
E N Kisangau ◽  
A Awour ◽  
B Juma ◽  
D Odhiambo ◽  
T Muasya ◽  
...  

Abstract Background Hepatitis B virus (HBV) is a vaccine-preventable infection that can spread in healthcare setting. Data on HBV infections and vaccine in African healthcare workers (HCWs) are limited. We estimated HBV infection prevalence, hepatitis B vaccination status and identified factors associated with vaccination in one Kenyan county. Methods Randomly selected HCWs completed a questionnaire about HBV exposure and self-reported immunization histories, and provided blood for testing of selected HBV biomarkers to assess HBV infection and vaccination status: HBV core antibodies (anti-HBc), HBV surface antigen (HBsAg) and HBV surface antibodies (anti-HBs). Prevalence odds ratios (OR) with 95% confidence intervals (95% CI) were calculated to identify factors associated with vaccination. Results Among 312 HCWs surveyed, median age was 31 years (range: 19–67 years). Of 295 blood samples tested, 13 (4%) were anti-HBc and HBsAg-positive evidencing chronic HBV infection; 139 (47%) had protective anti-HBs levels. Although 249 (80%) HCWs received ≥1 HBV vaccine dose, only 119 (48%) received all three recommended doses. Complete vaccination was more likely among those working in hospitals compared to those working in primary healthcare facilities (OR = 2.5; 95% CI: 1.4–4.3). Conclusion We recommend strengthening county HCW vaccination, and collecting similar data nationally to guide HBV prevention and control.


2018 ◽  
Vol 43 (2) ◽  
pp. 63-70
Author(s):  
Dilip Kumar Ghosh ◽  
Chanchal Kumar Ghosh ◽  
Mukta Nath ◽  
Syed Alamgir Safwath ◽  
Santosh Kumar Saha ◽  
...  

The infection with the Hepatitis B virus (HBV) is a global health problem. Hepatitis B virus (HBV) infections are rapidly spreading in developing countries due to the lack of health education, poverty, illiteracy and Hepatitis B vaccination. No widespread population based data of HBV is available in the country's aspect. So, a population-based serological survey was done to determine the prevalence of the Hepatitis B core antibody total (IgM+IgG) in an impoverished Urban Community in Dhaka, Bangladesh. A descriptive cross-sectional study was conducted among 384 healthy individuals and age between 18-60 years from the urban slum in Dhaka city. The study was implemented through collaboration with Shaheed Suhrawardy Medical College, Dhaka from January 2013 to June 2013. The study participants were selected through systematic sampling procedure and blood tested for anti-HBc. Anti-HBc estimations were carried out by VITROS Immune diagnostic assay. The study was pertained Ethical permission from Bangladesh Medical Research Council (BMRC) and every participant was informed regarding their written informed consent. Among the 384 respondents, 183(47.6%) individuals were positive for the core antibody of hepatitis B virus (anti-HBc). The anti HBc positive group consisted almost of equal number of male 93, (24.2%) and female 90 (23.4%). There was a significantly increasing prevalence of the core antibody among young adults and middle age of the respondents (28.7%). Major risk factors for exposure to Hepatitis B appeared to be Ear-nose-body piercing, Circumcision by Hajam, unsafe blood transfusion and unsterile dental intervention. High prevalence of hepatitis B Core antibody (47.6%) indicates that the members of this urban community are highly exposed to hepatitis B virus.


Vaccines ◽  
2021 ◽  
Vol 10 (1) ◽  
pp. 19
Author(s):  
Xinyao Liu ◽  
Wuqi Qiu ◽  
Yan Liang ◽  
Wei Zhang ◽  
Qian Qiu ◽  
...  

Evidence on the effectiveness of hepatitis B virus (HBV) infection screening and vaccination programs remains rare in China. We used a quasi-experimental method, propensity score matching, to evaluate the effects of a community-based HBV infection detection combined with vaccination (HBVIDV) program in a pilot. Data were retrieved from the HBVIDV program implemented between July 2019 and June 2020. Outcomes were the difference between the treatment and control groups in hepatitis B vaccination (≥1 dose), hepatitis B vaccine series completion (≥3 doses), and serologic evidence of vaccine-mediated immunity. Altogether, 26,180 individuals were included, where 6160 (23.5%) individuals were assigned to the treatment group, and 20,020 (76.5%) individuals were assigned to the control group. After propensity score matching, 5793 individuals were matched. The rates of hepatitis B vaccination, hepatitis B vaccine series completion, and prevalence of vaccine-mediated immunity in the treatment and control groups were 29.0% vs. 17.8%, 22.1% vs. 13.1%, and 38.2% vs. 27.6%, respectively. The HBVIDV program was significantly associated with increased hepatitis B vaccination rate (OR, 1.884, 95% CI 1.725–2.057), hepatitis B vaccine series completion rate (OR, 1.872, 95% CI 1.696–2.065), and prevalence of vaccine-mediated immunity (OR, 1.623, 95% CI 1.501–1.755). The greater magnitude of association between HBVIDV program and outcomes was observed among adults aged 35–54 years and adults who live in rural areas. The HBVIDV program was effective in increasing the hepatitis B vaccination rate, hepatitis B vaccine series completion rate, and prevalence of vaccine-mediated immunity among adults in the pilot. Further focusing the program on special populations and regions may produce more effective results.


2017 ◽  
Vol 11 (4) ◽  
Author(s):  
S. Rolland ◽  
L. Antonova ◽  
J. Powis ◽  
T. Murdoch ◽  
D. Wong ◽  
...  

Clinicians often assume that patients vaccinated for hepatitis B virus (HBV) have immunity. We report three cases of acute HBV infection in HBV-vaccinated HIV patients. These cases illustrate that patients at an elevated risk of HBV exposure presenting with acute hepatitis should be tested for HBV infection regardless of previous vaccination status.


Sign in / Sign up

Export Citation Format

Share Document